Medshine Discovery Inc.

Genentech, Inc.

Amlogic (shanghai) Co., Ltd.

Guangdong Raynovent Biotech Co., Ltd.

Constellation Pharmaceuticals, Inc.

Honeywell International Inc.

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Cstone Pharmaceuticals

Cstone Pharmaceuticals (shanghai) Co., Ltd.

Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.

Cstone Pharmaceuticals (suzhou) Co., Ltd.

Luoxin Pharmaceutical (shanghai) Co., Ltd.

Guangzhou Joyo Pharmatech Co., Ltd.

Phaeno Therapeutics Co., Ltd.

Chengdu Jinrui Foundation Biotech Co., Ltd.

Kevin X Chen

Shuhui Chen

Jian Li

Cheng Xie

Jian Xiong

Jingjing Wang

Fang Liu

Kai Zhou

Boyu Hu

John Zhong

Yanxin Yu

Peng Li

Xuanjia Peng

Xiaoxin Chen

Chaofeng Long

Zhaoguo Chen

Mike Yip

Robin Zhu

Joseph P Lyssikatos

Anthony A Estrada

Steven R Magnuson

Xiquan Zhang

F Anthony Romero

Snahel Patel

Guoping Hu

Vickie Hsiao-Wei Tsui

Michael Siu

Xin Tian

Kwong Wah Lai

Wen Liu

Jeremy M Murray

Xinde Chen

Fei Wang

Brian K Albrecht

Alan G Olivero

Alexander M Taylor

Yong Chen

Richard Pastor

Paul Gibbons

Aiming Zhang

Daniel Shore

Terry Crawford

Terry Kellar

Malcolm Huestis

Xiongbin Xu

Sarah Bronner

Haizhong Tan

Xiaofei Wang

Patrick Cyr

Linghui Wu

Sam Su

Liting Dong

Changyou Ma

John Wai

Guibai Liang

Xiaobing Yan

Xiawei Wei

Fen Jiang

Chunyu Shao

Nico Xu

Bing-Yan Zhu

Zheng Wang

Yves Leblanc

Michael Charles Hewitt

Hongjiang Xu

Wentao Wu

Tie-Lin Wang

Daniel J Burdick

Wen K Liu

Xiao Liu

Zhuowei Liu

Alexandre Cote

Zhen Gong

Alexandre Côté

Steven Elliot Kauder

Jiaqiang Dong

Jiangpeng Liao

Xiangjian Wang

Marc Adler

Jackson G Egen

Chengwu Liu

Minliang Xiao

Christopher G Nasveschuck

Shaohua Huang

Xiaoyuan Chen

Jiangfeng Lin

Haomin Chen

Yuekun Nie

Jianglei Huang

Xuejin Zhang

Zhulian Jiang

Huiyu Zhang

Jackson Egen

The present disclosure discloses a class of macrocyclic derivatives, and specifically discloses a compound shown in formula (VI), a stereoisomer thereof, and a pharmaceutically acceptable salt thereof.

Macrocyclic derivative and use thereof

The present invention discloses a class of anti-influenza virus compounds, and the use thereof in the preparation of a drug for treating diseases associated with influenza viruses. In particular, the present invention discloses a compound represented by formula (I) and a pharmaceutically acceptable salt thereof.

Anti-influenza virus pyrimidine derivatives

The present invention relates to a group of pyrrolo[2,1-f][1,2,4]triazine derivatives serving as selective HER2 inhibitors and an application thereof in the preparation of a drug that serves as an HER2 inhibitor. Specifically, the present invention relates to a compound represented by formula (I), an isomer thereof or a pharmaceutically acceptable salt thereof.

Pyrrolo[2,1-f][1,2,4]triazine derivatives serving as selective HER2 inhibitors and application thereof

Anti-influenza virus pyrimidine derivative

Disclosed in the present invention are a crystal form of a [1,2,4]triazolo[1,5-c]pyrimidine compound and a preparation method thereof. Further disclosed is a use of the crystal form in the preparation of a medicament for treating Areceptor related diseases. 

Crystal form a of (5-amino-8-(2-methyl-6-(trifluoromethyl)pyridin-4-yl)-7-phenyl-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)methanol (compound 1)

Disclosed is a novel class of MDM2-p53 inhibitor compounds having an imidaxopyrolone structure, and specifically disclosed are compounds represented by formulas (I-1) and (I-2) and pharmaceutically acceptable salts thereof. 

Substituted pyrrolo[3,4-d]imidazoles as MDM2-p53 inhibitors

Disclosed are a crystal form and a salt form of a pyrazolopridine compound, and a preparation method therefor. Further included is the use of the crystal form in preparing anti-influenza virus drugs.

Crystal form and salt form of pyridoimidazole compound and preparation method therefor

A bicyclic compound acting as a ROR&#x3b3; inhibitor. Provided are a compound of formula (I) or a pharmaceutically acceptable salt thereof, the compound having a structure as represented by formula (I-A) or formula (I-B). The provided compound of formula (I-A) or formula (I-B) or pharmaceutically acceptable salt thereof has good ROR&#x3b3; inhibitory activities, being expected to be used for treating diseases mediated by ROR&#x3b3; receptors in a mammal. 

Bicylic compound acting as an inhibitor

A borate compound of an azetidine derivative, relating in particular to a compound represented by formula (I) or a pharmaceutically acceptable salt thereof, a tautomer thereof, a stereoisomer thereof or a geometric isomer thereof, as well as a use thereof in the preparation of a drug used for the treatment or prevention of multiple myeloma. 

Borate of azetidine derivative

Disclosed are a series of pyridopyrimidine compounds and a use of same in the preparation of drugs associated with mTORC 1/2 dual complex inhibitors, and specifically disclosed is a use of the compounds as shown in formula (IV), tautomers thereof or pharmaceutically acceptable salts thereof in the preparation of drugs associated with mTORC 1/2 dual complex inhibitors. 

Pyridopyrimidine compounds acting as mTORC 1/2 dual inhibitors

Disclosed are a compound represented by formula (I) or a pharmaceutically acceptable salt thereof, and an application of the compound or slat in preparation of drugs for treating diseases related to an Areceptor. 

Fused ring derivative as Areceptor inhibitor

The present invention relates to a compound formula (I): and to salts thereof, wherein R, RX, and Y have any of the values defined herein, and compositions and uses thereof. The compounds are useful as inhibitors of CBP and/or EP300. Also included are pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various CBP and/or EP300-mediated disorders.

Therapeutic compounds and uses thereof

A crystal form A of a 3,4-dihydrothieno[3,2-d]pyrimidine compound (1), a preparation method therefor and an application thereof in the preparation of an anti-human cytomegalovirus (HCMV) drug. 

Crystal form of 3,4-dihydrothieno[3,2-d]pyrimidine compound and preparation method thereof

The present invention discloses a class of anti-influenza virus compounds, and the use thereof in the preparation of a drug for treating diseases associated with influenza viruses. In particular, the present invention discloses a compound represented by formula (I) and a pharmaceutically acceptable salt thereof. 

The present invention provides for compounds of Formula I-I and embodiments and salts thereof for the treatment of diseases (e.g., neurodegenerative diseases). R, R, R, X, X, A and Cy variable in Formula I-I all have the meaning as defined herein. 

Biheteroaryl compounds and uses thereof

Growing community of inventors

Shanghai, China

Kevin X Chen